サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1166024

がん診断の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）

Cancer Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
出版日: | 発行: Transparency Market Research | ページ情報: 英文 190 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.86円
がん診断の世界市場 - 業界分析、規模、シェア、成長、動向、予測（2022年～2031年）
出版日: 2022年10月21日
発行: Transparency Market Research
ページ情報: 英文 190 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のがん診断市場について調査分析し、市場動向、セグメント分析、地域分析、企業プロファイルなどを提供しています。

目次

第1章 序文

第2章 前提と調査手法

第3章 エグゼクティブサマリー：世界のがん診断市場

第4章 市場の概要

  • イントロダクション
    • セグメントの定義
  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • 世界のがん診断市場の分析と予測（2017年～2031年）
    • 市場収益予測

第5章 主要考察

  • がん診断における技術開発と新しいアプローチ
  • 世界の主要国におけるがんの有病率と発生率
  • 業界に対するCOVID-19パンデミックの影響（バリューチェーンと短期・中期・長期の影響）

第6章 世界のがん診断市場の分析と予測：検査タイプ別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額の予測：検査タイプ別（2017年～2031年）
    • 腫瘍バイオマーカー検査
    • 画像検査
    • 内視鏡検査
    • 生検
  • 市場魅力分析：検査タイプ別

第7章 世界のがん診断市場の分析と予測：用途別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額の予測：用途別（2017年～2031年）
    • 乳がん
    • 肺がん
    • 大腸がん
    • 前立腺がん
    • 膵臓がん
    • 血液がん
    • 卵巣がん
    • メラノーマ
    • その他のがん
  • 市場魅力分析：用途別

第8章 世界のがん診断市場の分析と予測：エンドユーザー別

  • イントロダクションと定義
  • 主な調査結果/発展
  • 市場金額の予測：エンドユーザー別（2017年～2031年）
    • 病院
    • 外来手術センター
    • 診断検査室
    • その他
  • 市場魅力分析：エンドユーザー別

第9章 世界のがん診断市場の分析と予測：地域別

  • 主な調査結果
  • 市場金額の予測：地域別
    • 北米
    • 欧州
    • アジア太平洋
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場魅力分析：地域別

第10章 北米のがん診断市場の分析と予測

  • イントロダクション
    • 主な調査結果
  • 市場金額の予測：検査タイプ別（2017年～2031年）
  • 市場金額の予測：用途別（2017年～2031年）
  • 市場金額の予測：エンドユーザー別（2017年～2031年）
  • 市場金額の予測：国別（2017年～2031年）
    • 米国
    • カナダ
  • 市場魅力分析
    • 検査タイプ別
    • 用途別
    • エンドユーザー別
    • 国別

第11章 欧州のがん診断市場の分析と予測

第12章 アジア太平洋のがん診断市場の分析と予測

第13章 ラテンアメリカのがん診断市場の分析と予測

第14章 中東・アフリカのがん診断市場の分析と予測

第15章 競合情勢

  • 市場企業 - 競合マトリックス：階層・企業規模別
  • 市場シェア分析：企業別（2021年）
  • 企業プロファイル
    • Abbott
    • Agilent Technologies, Inc.
    • Applied DNA Sciences
    • Becton, Dickinson and Company
    • bioMerieux SA
    • Eli Lilly and Company
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • General Electric Company
    • Hologic, Inc.
    • Illumina, Inc.
    • Menarini Silicon Biosystems
    • QIAGEN
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific, Inc.
図表

List of Tables

  • Table 01: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 02: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 03: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 04: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017-2031
  • Table 05: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017-2031
  • Table 06: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 07: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 08: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 09: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 10: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 11: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 12: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 13: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 14: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 15: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 16: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 17: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 18: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 19: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 20: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031
  • Table 21: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
  • Table 22: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017-2031
  • Table 23: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by Application, 2017-2031
  • Table 24: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017-2031

List of Figures

  • Figure 01: Global Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 02: Global Cancer Diagnostics Market Value Share, by Test Type, 2021
  • Figure 03: Global Cancer Diagnostics Market Value Share, by Application, 2021
  • Figure 04: Global Cancer Diagnostics Market Value Share, by End-user 2021
  • Figure 05: Global Cancer Diagnostics Market Value Share Analysis, by Test Type 2021 and 2031
  • Figure 06: Global Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 07: Global Cancer Diagnostics Market Value (US$ Mn), by Tumor Biomarker Tests, 2017-2031
  • Figure 08: Global Cancer Diagnostics Market Value (US$ Mn), by Prostate Specific Antigen Tests, 2017-2031
  • Figure 09: Global Cancer Diagnostics Market Value (US$ Mn), by Circulating Tumor Cells (CTC) Tests, 2017-2031
  • Figure 10: Global Cancer Diagnostics Market Value (US$ Mn), by Alpha-fetoprotein (AFP) Tests, 2017-2031
  • Figure 11: Global Cancer Diagnostics Market Value (US$ Mn), by CA 19-9 Tests, 2017-2031
  • Figure 12: Global Cancer Diagnostics Market Value (US$ Mn), by CA 125 Tests, 2017-2031
  • Figure 13: Global Cancer Diagnostics Market Value (US$ Mn), by HER2, 2017-2031
  • Figure 14: Global Cancer Diagnostics Market Value (US$ Mn), by BRCA, 2017-2031
  • Figure 15: Global Cancer Diagnostics Market Value (US$ Mn), by KRAS, 2017-2031
  • Figure 16: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 17: Global Cancer Diagnostics Market Value (US$ Mn), by Imaging, 2017-2031
  • Figure 18: Global Cancer Diagnostics Market Value (US$ Mn), by Magnetic Resonance Imaging (MRI) Scan, 2017-2031
  • Figure 19: Global Cancer Diagnostics Market Value (US$ Mn), by Positron Emission Tomography (PET) Scan, 2017-2031
  • Figure 20: Global Cancer Diagnostics Market Value (US$ Mn), by Computed Tomography (CT) Scan, 2017-2031
  • Figure 21: Global Cancer Diagnostics Market Value (US$ Mn), by Mammography, 2017-2031
  • Figure 22: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 23: Global Cancer Diagnostics Market Value (US$ Mn), by Endoscopy, 2017-2031
  • Figure 24: Global Cancer Diagnostics Market Value (US$ Mn), by Colonoscopy, 2017-2031
  • Figure 25: Global Cancer Diagnostics Market Value (US$ Mn), by Bronchoscopy, 2017-2031
  • Figure 26: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 27: Global Cancer Diagnostics Market Value (US$ Mn), by Biopsy, 2017-2031
  • Figure 28: Global Cancer Diagnostics Market Value (US$ Mn), by Bone Marrow Biopsy, 2017-2031
  • Figure 29: Global Cancer Diagnostics Market Value (US$ Mn), by Needle Biopsy, 2017-2031
  • Figure 30: Global Cancer Diagnostics Market Value (US$ Mn), by Endoscopic Biopsy, 2017-2031
  • Figure 31: Global Cancer Diagnostics Market Value (US$ Mn), by Others, 2017-2031
  • Figure 32: Global Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 33: Global Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 34: Global Cancer Diagnostics Market Revenue (US$ Mn), by Breast Cancer, 2017-2031
  • Figure 35: Global Cancer Diagnostics Market Revenue (US$ Mn), by Lung Cancer, 2017-2031
  • Figure 36: Global Cancer Diagnostics Market Revenue (US$ Mn), by Colorectal Cancer, 2017-2031
  • Figure 37: Global Cancer Diagnostics Market Revenue (US$ Mn), by Prostate Cancer, 2017-2031
  • Figure 38: Global Cancer Diagnostics Market Revenue (US$ Mn), by Pancreatic Cancer, 2017-2031
  • Figure 39: Global Cancer Diagnostics Market Revenue (US$ Mn), by Ovarian Cancer, 2017-2031
  • Figure 40: Global Cancer Diagnostics Market Revenue (US$ Mn), by Blood Cancer, 2017-2031
  • Figure 41: Global Cancer Diagnostics Market Revenue (US$ Mn), by Melanoma, 2017-2031
  • Figure 42: Global Cancer Diagnostics Market Revenue (US$ Mn), by Other Cancers, 2017-2031
  • Figure 43: Global Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 44: Global Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 45: Global Cancer Diagnostics Market Revenue (US$ Mn), by Hospitals 2017-2031
  • Figure 46: Global Cancer Diagnostics Market Revenue (US$ Mn), by Ambulatory Surgical Centers, 2017-2031
  • Figure 47: Global Cancer Diagnostics Market Revenue (US$ Mn), by Diagnostic Laboratories, 2017-2031
  • Figure 48: Global Cancer Diagnostics Market Revenue (US$ Mn), by Others, 2017-2031
  • Figure 49: Global Cancer Diagnostics Market Value Share Analysis, by Region, 2021 and 2031
  • Figure 50: Global Cancer Diagnostics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 51: North America Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 52: North America Cancer Diagnostics Market Value Share Analysis, by Country, 2021 and 2031
  • Figure 53: North America Cancer Diagnostics Market Attractiveness Analysis, by Country, 2022-2031
  • Figure 54: North America Cancer Diagnostics Market Value Share Analysis, by Test Type , 2021 and 2031
  • Figure 55: North America Cancer Diagnostics Market Attractiveness Analysis, by Test Type 2022-2031
  • Figure 56: North America Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 57: North America Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 58: North America Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 59: North America Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 60: Europe Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 61: Europe Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 62: Europe Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 63: Europe Cancer Diagnostics Market Value Share Analysis, by Test Type 2021 and 2031
  • Figure 64: Europe Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 65: Europe Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 66: Europe Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 67: Europe Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 68: Europe Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 69: Asia Pacific Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 70: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 71: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2022-2031
  • Figure 72: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 73: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 74: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 75: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 76: Asia Pacific Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 77: Asia Pacific Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 78: Latin America Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 79: Latin America Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 80: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 81: Latin America Cancer Diagnostics Market Value Share Analysis, by Test Type, 2021 and 2031
  • Figure 82: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 83: Latin America Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 84: Latin America Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 85: Latin America Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 86: Latin America Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 87: Middle East & Africa Cancer Diagnostics Market Value (US$ Mn) Forecast, 2017-2031
  • Figure 88: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Country/Sub-region, 2021 and 2031
  • Figure 89: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2031
  • Figure 90: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Test Type , 2021 and 2031
  • Figure 91: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Test Type, 2022-2031
  • Figure 92: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by Application, 2021 and 2031
  • Figure 93: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by Application, 2022-2031
  • Figure 94: Middle East & Africa Cancer Diagnostics Market Value Share Analysis, by End-user, 2021 and 2031
  • Figure 95: Middle East & Africa Cancer Diagnostics Market Attractiveness Analysis, by End-user, 2022-2031
  • Figure 96: Company Share Analysis, 2021
目次
Product Code: TMRGL3637

TMR's report on the global cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global cancer diagnostics market for the period 2017-2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global cancer diagnostics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the cancer diagnostics market.

The report delves into the competitive landscape of the global cancer diagnostics market. Key players operating in the global cancer diagnostics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global cancer diagnostics market profiled in this report.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cancer Diagnostics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Segment Definition
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Cancer Diagnostics Market Analysis and Forecast, 2017-2031
    • 4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

  • 5.1. Technological Developments & New Approaches in Cancer Diagnosis
  • 5.2. Cancer Prevalence & Incidence Rate Globally with Key Countries
  • 5.3. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/ Mid-/Long-term Impact)

6. Global Cancer Diagnostics Market Analysis and Forecast, by Test Type

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Test Type, 2017-2031
    • 6.3.1. Tumor Biomarker Tests
      • 6.3.1.1. Prostate Specific Antigen Tests
      • 6.3.1.2. Circulating Tumor Cells (CTC) Tests
      • 6.3.1.3. Alpha-fetoprotein (AFP) Tests
      • 6.3.1.4. CA 19-9 Tests
      • 6.3.1.5. CA 125 Tests
      • 6.3.1.6. HER2
      • 6.3.1.7. BRCA
      • 6.3.1.8. KRAS
      • 6.3.1.9. Others
    • 6.3.2. Imaging
      • 6.3.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 6.3.2.2. Positron Emission Tomography (PET) Scan
      • 6.3.2.3. Computed Tomography (CT) Scan
      • 6.3.2.4. Mammography
      • 6.3.2.5. Others
    • 6.3.3. Endoscopy
      • 6.3.3.1. Colonoscopy
      • 6.3.3.2. Bronchoscopy
      • 6.3.3.3. Others
    • 6.3.4. Biopsy
      • 6.3.4.1. Bone Marrow Biopsy
      • 6.3.4.2. Needle Biopsy
      • 6.3.4.3. Endoscopic Biopsy
      • 6.3.4.4. Others
  • 6.4. Market Attractiveness Analysis, by Test Type

7. Global Cancer Diagnostics Market Analysis and Forecast, by Application

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Application, 2017-2031
    • 7.3.1. Breast Cancer
    • 7.3.2. Lung Cancer
    • 7.3.3. Colorectal Cancer
    • 7.3.4. Prostate Cancer
    • 7.3.5. Pancreatic Cancer
    • 7.3.6. Blood Cancer
    • 7.3.7. Ovarian Cancer
    • 7.3.8. Melanoma
    • 7.3.9. Other Cancers
  • 7.4. Market Attractiveness Analysis, by Application

8. Global Cancer Diagnostics Market Analysis and Forecast, by End-user

  • 8.1. Introduction & Definition
  • 8.2. Key Findings / Developments
  • 8.3. Market Value Forecast, by End-user, 2017-2031
    • 8.3.1. Hospitals
    • 8.3.2. Ambulatory Surgical Centers
    • 8.3.3. Diagnostic Laboratories
    • 8.3.4. Others
  • 8.4. Market Attractiveness Analysis, by End-user

9. Global Cancer Diagnostics Market Analysis and Forecast, by Region

  • 9.1. Key Findings
  • 9.2. Market Value Forecast, by Region
    • 9.2.1. North America
    • 9.2.2. Europe
    • 9.2.3. Asia Pacific
    • 9.2.4. Latin America
    • 9.2.5. Middle East & Africa
  • 9.3. Market Attractiveness Analysis, by Region

10. North America Cancer Diagnostics Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Test Type, 2017-2031
    • 10.2.1. Tumor Biomarker Tests
      • 10.2.1.1. Prostate Specific Antigen Tests
      • 10.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 10.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 10.2.1.4. CA 19-9 Tests
      • 10.2.1.5. CA 125 Tests
      • 10.2.1.6. HER2
      • 10.2.1.7. BRCA
      • 10.2.1.8. KRAS
      • 10.2.1.9. Others
    • 10.2.2. Imaging
      • 10.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 10.2.2.2. Positron Emission Tomography (PET) Scan
      • 10.2.2.3. Computed Tomography (CT) Scan
      • 10.2.2.4. Mammography
      • 10.2.2.5. Others
    • 10.2.3. Endoscopy
      • 10.2.3.1. Colonoscopy
      • 10.2.3.2. Bronchoscopy
      • 10.2.3.3. Others
    • 10.2.4. Biopsy
      • 10.2.4.1. Bone Marrow Biopsy
      • 10.2.4.2. Needle Biopsy
      • 10.2.4.3. Endoscopic Biopsy
      • 10.2.4.4. Others
  • 10.3. Market Value Forecast, by Application, 2017-2031
    • 10.3.1. Breast Cancer
    • 10.3.2. Lung Cancer
    • 10.3.3. Colorectal Cancer
    • 10.3.4. Prostate Cancer
    • 10.3.5. Blood Cancer
    • 10.3.6. Pancreatic Cancer
    • 10.3.7. Ovarian Cancer
    • 10.3.8. Melanoma
    • 10.3.9. Other Cancers
  • 10.4. Market Value Forecast, by End-user, 2017-2031
    • 10.4.1. Hospitals
    • 10.4.2. Ambulatory Surgical Centers
    • 10.4.3. Diagnostic Laboratories
    • 10.4.4. Others
  • 10.5. Market Value Forecast, by Country, 2017-2031
    • 10.5.1. U.S.
    • 10.5.2. Canada
  • 10.6. Market Attractiveness Analysis
    • 10.6.1. By Test Type
    • 10.6.2. By Application
    • 10.6.3. By End-user
    • 10.6.4. By Country

11. Europe Cancer Diagnostics Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Test Type, 2017-2031
    • 11.2.1. Tumor Biomarker Tests
      • 11.2.1.1. Prostate Specific Antigen Tests
      • 11.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 11.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 11.2.1.4. CA 19-9 Tests
      • 11.2.1.5. CA 125 Tests
      • 11.2.1.6. HER2
      • 11.2.1.7. BRCA
      • 11.2.1.8. KRAS
      • 11.2.1.9. Others
    • 11.2.2. Imaging
      • 11.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 11.2.2.2. Positron Emission Tomography (PET) Scan
      • 11.2.2.3. Computed Tomography (CT) Scan
      • 11.2.2.4. Mammography
      • 11.2.2.5. Others
    • 11.2.3. Endoscopy
      • 11.2.3.1. Colonoscopy
      • 11.2.3.2. Bronchoscopy
      • 11.2.3.3. Others
    • 11.2.4. Biopsy
      • 11.2.4.1. Bone Marrow Biopsy
      • 11.2.4.2. Needle Biopsy
      • 11.2.4.3. Endoscopic Biopsy
      • 11.2.4.4. Others
  • 11.3. Market Value Forecast, by Application, 2017-2031
    • 11.3.1. Breast Cancer
    • 11.3.2. Lung Cancer
    • 11.3.3. Colorectal Cancer
    • 11.3.4. Prostate Cancer
    • 11.3.5. Pancreatic Cancer
    • 11.3.6. Ovarian Cancer
    • 11.3.7. Blood Cancer
    • 11.3.8. Melanoma
    • 11.3.9. Other Cancers
  • 11.4. Market Value Forecast, by End-user, 2017-2031
    • 11.4.1. Hospitals
    • 11.4.2. Ambulatory Surgical Centers
    • 11.4.3. Diagnostic Laboratories
    • 11.4.4. Others
  • 11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 11.5.1. Germany
    • 11.5.2. U.K.
    • 11.5.3. France
    • 11.5.4. Italy
    • 11.5.5. Spain
    • 11.5.6. Rest of Europe
  • 11.6. Market Attractiveness Analysis
    • 11.6.1. By Test Type
    • 11.6.2. By Application
    • 11.6.3. By End-user
    • 11.6.4. By Country/Sub-region

12. Asia Pacific Cancer Diagnostics Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Test Type, 2017-2031
    • 12.2.1. Tumor Biomarker Tests
      • 12.2.1.1. Prostate Specific Antigen Tests
      • 12.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 12.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 12.2.1.4. CA 19-9 Tests
      • 12.2.1.5. CA 125 Tests
      • 12.2.1.6. HER2
      • 12.2.1.7. BRCA
      • 12.2.1.8. KRAS
      • 12.2.1.9. Others
    • 12.2.2. Imaging
      • 12.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 12.2.2.2. Positron Emission Tomography (PET) Scan
      • 12.2.2.3. Computed Tomography (CT) Scan
      • 12.2.2.4. Mammography
      • 12.2.2.5. Others
    • 12.2.3. Endoscopy
      • 12.2.3.1. Colonoscopy
      • 12.2.3.2. Bronchoscopy
      • 12.2.3.3. Others
    • 12.2.4. Biopsy
      • 12.2.4.1. Bone Marrow Biopsy
      • 12.2.4.2. Needle Biopsy
      • 12.2.4.3. Endoscopic Biopsy
      • 12.2.4.4. Others
  • 12.3. Market Value Forecast, by Application, 2017-2031
    • 12.3.1. Breast Cancer
    • 12.3.2. Lung Cancer
    • 12.3.3. Colorectal Cancer
    • 12.3.4. Prostate Cancer
    • 12.3.5. Pancreatic Cancer
    • 12.3.6. Ovarian Cancer
    • 12.3.7. Blood Cancer
    • 12.3.8. Melanoma
    • 12.3.9. Other Cancers
  • 12.4. Market Value Forecast, by End-user, 2017-2031
    • 12.4.1. Hospitals
    • 12.4.2. Ambulatory Surgical Centers
    • 12.4.3. Diagnostic Laboratories
    • 12.4.4. Others
  • 12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 12.5.1. China
    • 12.5.2. Japan
    • 12.5.3. India
    • 12.5.4. Australia & New Zealand
    • 12.5.5. Rest of Asia Pacific
  • 12.6. Market Attractiveness Analysis
    • 12.6.1. By Test Type
    • 12.6.2. By Application
    • 12.6.3. By End-user
    • 12.6.4. By Country/Sub-region

13. Latin America Cancer Diagnostics Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Test Type, 2017-2031
    • 13.2.1. Tumor Biomarker Tests
      • 13.2.1.1. Prostate Specific Antigen Tests
      • 13.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 13.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 13.2.1.4. CA 19-9 Tests
      • 13.2.1.5. CA 125 Tests
      • 13.2.1.6. HER2
      • 13.2.1.7. BRCA
      • 13.2.1.8. KRAS
      • 13.2.1.9. Others
    • 13.2.2. Imaging
      • 13.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 13.2.2.2. Positron Emission Tomography (PET) Scan
      • 13.2.2.3. Computed Tomography (CT) Scan
      • 13.2.2.4. Mammography
      • 13.2.2.5. Others
    • 13.2.3. Endoscopy
      • 13.2.3.1. Colonoscopy
      • 13.2.3.2. Bronchoscopy
      • 13.2.3.3. Others
    • 13.2.4. Biopsy
      • 13.2.4.1. Bone Marrow Biopsy
      • 13.2.4.2. Needle Biopsy
      • 13.2.4.3. Endoscopic Biopsy
      • 13.2.4.4. Others
  • 13.3. Market Value Forecast, by Application, 2017-2031
    • 13.3.1. Breast Cancer
    • 13.3.2. Lung Cancer
    • 13.3.3. Colorectal Cancer
    • 13.3.4. Prostate Cancer
    • 13.3.5. Melanoma
    • 13.3.6. Pancreatic Cancer
    • 13.3.7. Blood Cancer
    • 13.3.8. Ovarian Cancer
    • 13.3.9. Other Cancers
  • 13.4. Market Value Forecast, by End-user, 2017-2031
    • 13.4.1. Hospitals
    • 13.4.2. Ambulatory Surgical Centers
    • 13.4.3. Diagnostic Laboratories
    • 13.4.4. Others
  • 13.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 13.5.1. Brazil
    • 13.5.2. Mexico
    • 13.5.3. Rest of Latin America
  • 13.6. Market Attractiveness Analysis
    • 13.6.1. By Test Type
    • 13.6.2. By Application
    • 13.6.3. By End-user
    • 13.6.4. By Country/Sub-region

14. Middle East & Africa Cancer Diagnostics Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Test Type, 2017-2031
    • 14.2.1. Tumor Biomarker Tests
      • 14.2.1.1. Prostate Specific Antigen Tests
      • 14.2.1.2. Circulating Tumor Cells (CTC) Tests
      • 14.2.1.3. Alpha-fetoprotein (AFP) Tests
      • 14.2.1.4. CA 19-9 Tests
      • 14.2.1.5. CA 125 Tests
      • 14.2.1.6. HER2
      • 14.2.1.7. BRCA
      • 14.2.1.8. KRAS
      • 14.2.1.9. Others
    • 14.2.2. Imaging
      • 14.2.2.1. Magnetic Resonance Imaging (MRI) Scan
      • 14.2.2.2. Positron Emission Tomography (PET) Scan
      • 14.2.2.3. Computed Tomography (CT) Scan
      • 14.2.2.4. Mammography
      • 14.2.2.5. Others
    • 14.2.3. Endoscopy
      • 14.2.3.1. Colonoscopy
      • 14.2.3.2. Bronchoscopy
      • 14.2.3.3. Others
    • 14.2.4. Biopsy
      • 14.2.4.1. Bone Marrow Biopsy
      • 14.2.4.2. Needle Biopsy
      • 14.2.4.3. Endoscopic Biopsy
      • 14.2.4.4. Others
  • 14.3. Market Value Forecast, by Application, 2017-2031
    • 14.3.1. Breast Cancer
    • 14.3.2. Lung Cancer
    • 14.3.3. Colorectal Cancer
    • 14.3.4. Prostate Cancer
    • 14.3.5. Pancreatic Cancer
    • 14.3.6. Ovarian Cancer
    • 14.3.7. Blood Cancer
    • 14.3.8. Melanoma
    • 14.3.9. Other Cancers
  • 14.4. Market Value Forecast, by End-user, 2017-2031
    • 14.4.1. Hospitals
    • 14.4.2. Ambulatory Surgical Centers
    • 14.4.3. Diagnostic Laboratories
    • 14.4.4. Others
  • 14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
    • 14.5.1. GCC Countries
    • 14.5.2. South Africa
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. Market Attractiveness Analysis
    • 14.6.1. By Test Type
    • 14.6.2. By Application
    • 14.6.3. By End-user
    • 14.6.4. By Country/Sub-region

15. Competition Landscape

  • 15.1. Market Player - Competition Matrix (by tier and size of companies)
  • 15.2. Market Share Analysis, by Company, 2021
  • 15.3. Company Profiles
    • 15.3.1. Abbott
      • 15.3.1.1. Company Overview
      • 15.3.1.2. Product Portfolio
      • 15.3.1.3. SWOT Analysis
      • 15.3.1.4. Financial Overview
      • 15.3.1.5. Strategic Overview
    • 15.3.2. Agilent Technologies, Inc.
      • 15.3.2.1. Company Overview
      • 15.3.2.2. Product Portfolio
      • 15.3.2.3. SWOT Analysis
      • 15.3.2.4. Financial Overview
      • 15.3.2.5. Strategic Overview
    • 15.3.3. Applied DNA Sciences
      • 15.3.3.1. Company Overview
      • 15.3.3.2. Product Portfolio
      • 15.3.3.3. SWOT Analysis
      • 15.3.3.4. Financial Overview
      • 15.3.3.5. Strategic Overview
    • 15.3.4. Becton, Dickinson and Company
      • 15.3.4.1. Company Overview
      • 15.3.4.2. Product Portfolio
      • 15.3.4.3. SWOT Analysis
      • 15.3.4.4. Financial Overview
      • 15.3.4.5. Strategic Overview
    • 15.3.5. bioMerieux SA
      • 15.3.5.1. Company Overview
      • 15.3.5.2. Product Portfolio
      • 15.3.5.3. SWOT Analysis
      • 15.3.5.4. Financial Overview
      • 15.3.5.5. Strategic Overview
    • 15.3.6. Eli Lilly and Company
      • 15.3.6.1. Company Overview
      • 15.3.6.2. Product Portfolio
      • 15.3.6.3. SWOT Analysis
      • 15.3.6.4. Financial Overview
      • 15.3.6.5. Strategic Overview
    • 15.3.7. Exact Sciences Corporation
      • 15.3.7.1. Company Overview
      • 15.3.7.2. Product Portfolio
      • 15.3.7.3. SWOT Analysis
      • 15.3.7.4. Financial Overview
      • 15.3.7.5. Strategic Overview
    • 15.3.8. F. Hoffmann-La Roche Ltd.
      • 15.3.8.1. Company Overview
      • 15.3.8.2. Product Portfolio
      • 15.3.8.3. SWOT Analysis
      • 15.3.8.4. Financial Overview
      • 15.3.8.5. Strategic Overview
    • 15.3.9. General Electric Company
      • 15.3.9.1. Company Overview
      • 15.3.9.2. Product Portfolio
      • 15.3.9.3. SWOT Analysis
      • 15.3.9.4. Financial Overview
      • 15.3.9.5. Strategic Overview
    • 15.3.10. Hologic, Inc.
      • 15.3.10.1. Company Overview
      • 15.3.10.2. Product Portfolio
      • 15.3.10.3. SWOT Analysis
      • 15.3.10.4. Financial Overview
      • 15.3.10.5. Strategic Overview
    • 15.3.11. Illumina, Inc.
      • 15.3.11.1. Company Overview
      • 15.3.11.2. Product Portfolio
      • 15.3.11.3. SWOT Analysis
      • 15.3.11.4. Financial Overview
      • 15.3.11.5. Strategic Overview
    • 15.3.12. Menarini Silicon Biosystems
      • 15.3.12.1. Company Overview
      • 15.3.12.2. Product Portfolio
      • 15.3.12.3. SWOT Analysis
      • 15.3.12.4. Financial Overview
      • 15.3.12.5. Strategic Overview
    • 15.3.13. QIAGEN
      • 15.3.13.1. Company Overview
      • 15.3.13.2. Product Portfolio
      • 15.3.13.3. SWOT Analysis
      • 15.3.13.4. Financial Overview
      • 15.3.13.5. Strategic Overview
    • 15.3.14. Siemens Healthcare GmbH
      • 15.3.14.1. Company Overview
      • 15.3.14.2. Product Portfolio
      • 15.3.14.3. SWOT Analysis
      • 15.3.14.4. Financial Overview
      • 15.3.14.5. Strategic Overview
    • 15.3.15. Thermo Fisher Scientific, Inc.
      • 15.3.15.1. Company Overview
      • 15.3.15.2. Product Portfolio
      • 15.3.15.3. SWOT Analysis
      • 15.3.15.4. Financial Overview
      • 15.3.15.5. Strategic Overview